

High-density lipoprotein cholesterol and cause-specific mortality: A population-based study of more than 630,000 individuals without prior cardiovascular conditions

Dennis T. Ko, MD, MSc; David A. Alter, MD, PhD; Helen Guo, MSc; Maria Koh, MSc; Geoffrey Lau, BHSc; Peter C. Austin, PhD; Gillian L. Booth, MD, MSc; William Hogg, MD; Cynthia A. Jackevicius, PharmD, MSc; Douglas S. Lee, MD, PhD; Harindra C. Wijeysundera, MD, PhD; John T. Wilkins, MD; and Jack V. Tu, MD, PhD for the Canadian Cardiovascular Health in Ambulatory Care Research Team CANHEART

AHA Clinical Science Special Report: November 10, 2015







Background

- Epidemiological data have suggested a protective dose-response relationship between HDL cholesterol levels and cardiovascular outcomes
- More recently, the importance of HDL cholesterol as a modifiable risk factor for heart disease has come under debate
- Niacin and cholesteryl ester transfer protein (CETP) inhibitors have shown an ability to raise HDL cholesterol levels substantially, but have not improved clinical outcomes
- Mendelian randomization studies have demonstrated some genetic mechanisms that raise HDL cholesterol levels are not associated with lower risk of myocardial infarction

Background

- Conventional knowledge on the relationship between HDL cholesterol levels and cardiovascular events has primarily come from observational studies such as the Framingham Heart study
- Potential limitations:
 - Smaller numbers of patients that precluded evaluation of the full spectrum of HDL levels
 - Few studies evaluated the relationship of HDL with noncardiac events
 - Relationship may have changed because of contemporary treatment

Study objective

To reappraise the epidemiological relationship of HDL cholesterol levels with mortality in a large unselected population without preexisting cardiovascular conditions

 A "big data" approach to examine the full spectrum of HDL cholesterol levels and causespecific mortality

CANHEART cohort data sources

Socio-demographics	CV Risk Factors and Co- morbidities	Health Care Services and Medications	Clinical Outcomes			
Registered Persons Database (RPDB)	Canadian Community Health Survey (CCHS)	ON Health Insurance Plan Physician Claims Database (OHIP)	CIHI Discharge Abstract Database (CIHI DAD) CIHI National Amb. Care Reporting System (NACRS)			
Citizenship & Immigration Canada Permanent Resident DB	Gamma-Dynacare Medical Laboratories (GDML)	ICES Physician Database (IPDB)				
Ontario Visible Minority Database	Ontario Diabetes Database (ODD)	Ontario Drug Benefit Database (ODB)	Registrar General of Ontario Vital Statistics (ORGD)			
	Ontario Hypertension Database (OHD)					
	EMRALD (EMR)	· · · · ·	GDML performs ~ 1/3 of all Ontario's			
	Ontario Chronic Obstructive Pulmonary Disease Database (COPD)	outpatient laboratory testing				
	Ontario Asthma Database (ASTHMA)					
	Ontario Cancer Registry (OCR)	Linked with encoded personal identifiers CIHI=Canadian Institute for Health Information EMRALD=Electronic Medical Record Administrative Data Linked Datab				

Study sample

Inclusions:

- Ontario residents on January 1st, 2008, 40 to 105 years old, valid health card number
- Outpatient cholesterol level in the year prior to the cohort inception (i.e. Jan 1 to Dec 31 2007)
- Exclusions:
 - Cardiovascular disease (myocardial infarction, heart failure, stroke, coronary revascularization)
 - Comorbidities (cancer, dementia, peripheral vascular disease, abdominal aortic aneurysm, venous thrombosis)
 - Nursing home residents

Sample size = 631,762

Methods


Outcomes

- Cardiovascular mortality
- Cancer mortality
- Other (non-cardiovascular, non-cancer) mortality
- Cause-specific Cox proportional hazard models that accounted for the competing risk of other types of causespecific deaths
 - Final model adjusted for age, income, smoking, hypertension, diabetes, non-HDL, triglyceride, medical comorbidities (respiratory, neurological, renal, rheumatologic, bleeding disorder, sepsis, major psychiatric disorder, history of respiratory failure/shock, trauma), and the Aggregated Diagnosis Groups

Baseline characteristics


	HDL Cholesterol (mg/dL)								
	≤30	31-40	41-50	51-60	61-70	71-80	81-90	>90	
	N=12,542	N=91,932	N=171,043	N=155,845	N=102,045	N=54,459	N=25,952	N=17,944	
Mean age, years	55.4	56.1	56.9	57.5	57.7	57.9	58.1	58.7	
Female, %	20.1	28.1	43.5	59.6	71.7	79.8	84.4	86.4	
Low income, %	20.4	18.4	17.0	15.9	15.1	14.0	13.2	13.3	
Hypertension, %	49.4	47.8	46.4	43.2	39.6	36.3	34.7	35.5	
Diabetes, %	38.0	29.6	23.6	17.8	13.5	10.8	9.1	9.0	
Smoker, %	25.2	21.6	18.0	14.0	16.0	12.5	16.9	13.0	
COPD, %	11.2	9.6	9.1	8.5	8.3	8.1	8.3	9.2	
Total cholesterol, mean (mg/dl)	171.4	187.6	196.6	202.5	207.3	212.4	217.8	228.9	

Age-standardized mortality in women




8,613 deaths during follow-up of 4.9 years. Error bars correspond to 95% Cl. Rate standardized to the 2006 Ontario census.

Adjusted hazard ratios in women




Age-standardized mortality in men



9,339 deaths during follow-up of 4.9 years. Error bars correspond to 95% Cl. Rate standardized to the 2006 Ontario census.

Adjusted hazard ratios in men



HDL-C (mg/dL)

Additional analysis

Subgroup analyses stratified by i) LDL cholesterol levels (< 100 mg/dL, > 100 mg/dL), ii) statin user and nonusers for individuals older than 65 years showed similar results

- 5,108 participants in the detailed Canadian Community Health Survey showed higher HDL cholesterol levels associated with lifestyle:
 - Lower BMI (<25 kg/m2)
 - Moderate physical activity (≥30 minutes walking/day)
 - Fruit and vegetable consumptions (≥5 servings/day)
 - Heavy alcohol use (≥5 drinks per occasion at least once a month during the year preceding the survey)

Limitations

- Did not have the ability to examine other aspects of HDL cholesterol such as particle sizes, subclasses, or function
- Laboratory data source included approximately one third of all outpatient cholesterol tests in Ontario. We have demonstrated that data are representative of the overall Ontario population
- Causes of death are based on death certificates which have not been independently adjudicated

Conclusions

- HDL cholesterol levels are associated with many socioeconomic, lifestyle, and comorbidity factors
- "U-shaped" response between HDL cholesterol levels and outcomes were observed particularly in men where individuals had higher risks of death at low and very high HDL cholesterol levels
- Similar relationship between HDL cholesterol levels and the risk of both cardiac and non-cardiac deaths
- HDL is unlikely to represent a cardiovascular specific riskfactor given similarities in its associations with noncardiovascular outcomes